Melatonin Impact on the Outcomes of Myocardial Ischemia/Reperfusion Injury During Coronary Artery Bypass Grafting Surgery
Primary Purpose
Coronary Artery Bypass Grafting, Coronary Artery Disease
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Melatonin
placebo
Sponsored by
About this trial
This is an interventional treatment trial for Coronary Artery Bypass Grafting focused on measuring CABG, melatonin, inflammation
Eligibility Criteria
Inclusion Criteria:
- Patients who will undergo elective CABG,
- ready to participate in the study and
- can be reached by phone
Exclusion Criteria:
• Patients who will require urgent surgery and won't have adequate time to take medications for 5 days,
- Re-operative patients (CABG),
- Off-pump CABG,
- Patients who have concomitant renal failure,
- Patients with severe respiratory problems.
- Patients with previous stroke or significant cerebrovascular disease,
- Patients with hepatitis b,c and HIV.
- Inflammatory disease ex. Rheumatoid arthritis, psoriasis…,
- Patients with ejection fraction (EF%) lower than 40%,
- Patients undergo CABG surgery with simultaneous heart valve repair or replacement, resection of a ventricular aneurysm, or other operations.
- Pregnancy and lactation.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Melatonin group
Control group
Arm Description
Melatonin Group (n=11) patients will receive 60 mg/day Melatonin capsule (M1) from the day five before surgery.
Control group (n=11) patients will receive placebos with the same appearances and packaging at the same dose and time as those in the melatonin group.
Outcomes
Primary Outcome Measures
Nuclear factor-kB (NF-κB)
Nuclear factor-kappa B (NF-κB) is a ubiquitous transcription factor that is involved in inflammatory and immune responses, as well as in regulation of expression of many other genes related to cell survival, proliferation, and differentiation
Secondary Outcome Measures
interleukin 6 il-6
Interleukin-6 is a widely used cytokine that causes inflammation and oxidative stress, which would further result in cardiac and cerebral injury. The increased expression of interleukin-6 is closely related to atherosclerosis, myocardial infarction, heart failure and ischemic stroke. It is a key risk factor for these diseases by triggering inflammatory reaction and inducing other molecules release.
Tumor necrosis factor alpha TNF-α
Tumor necrosis factor (TNF) is a multifunctional cytokine that plays important roles in diverse cellular events such as cell survival, proliferation, differentiation, and death. As a pro-inflammatory cytokine, TNF is secreted by inflammatory cells, which may be involved in inflammation-associated heart diseases.
cardiac troponins
cardiac marker
Full Information
NCT ID
NCT05552586
First Posted
September 21, 2022
Last Updated
September 21, 2022
Sponsor
Ain Shams University
1. Study Identification
Unique Protocol Identification Number
NCT05552586
Brief Title
Melatonin Impact on the Outcomes of Myocardial Ischemia/Reperfusion Injury During Coronary Artery Bypass Grafting Surgery
Official Title
The Effect of Melatonin on the Outcomes of Myocardial Ischemia/Reperfusion Injury During Coronary Artery Bypass Grafting Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
September 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 2022 (Anticipated)
Primary Completion Date
July 2023 (Anticipated)
Study Completion Date
September 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ain Shams University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The ischemia/reperfusion (I/R) injury of the myocardium initiates a variety and complex sets of inflammatory reactions that may both exaggerate local injury as well as provoke injury of distant organ function . I/R injuries are the main causes of heart failure, morbidity, and mortality after cardiac surgery such as coronary artery bypass graft (CABG surgery) . The reactive oxygen species are believed to be excessively elevated during coronary artery bypass surgery (CABG) due to compromised free radical scavenging mechanism in the myocardium that can make myocardium highly susceptible to oxidative stress and inflammation and result in reperfusion injury .
Melatonin and its metabolites protect against inflammation by regulating several inflammatory cytokines. Additionally, melatonin is a free radical scavenger and an antioxidant agent.
the current study is designed to investigate the protective effects of melatonin against myocardial I/R injury in patients undergoing coronary artery bypass grafting (CABG) surgery.
Detailed Description
Myocardial ischemia is a situation where there is an inadequate blood and oxygen supply to the heart muscles due to partial or complete obstruction of the coronary arteries, predisposing the affected cardiac muscle to death. Hence, restoration of blood supply is critical to reestablish myocardial reperfusion. The ischemia/reperfusion (I/R) injury of the myocardium initiates a variety and complex sets of inflammatory reactions that may both exaggerate local injury as well as provoke injury of distant organ function . I/R injuries are the main causes of heart failure, morbidity, and mortality after cardiac surgery such as coronary artery bypass graft (CABG surgery) . The reactive oxygen species are believed to be excessively elevated during coronary artery bypass surgery (CABG) due to compromised free radical scavenging mechanism in the myocardium that can make myocardium highly susceptible to oxidative stress and inflammation and result in reperfusion injury . Strategies to improve the CABG related complications are much needed to augment the positive outcomes in the post-operative surviving patients. There are various therapeutic approaches to decrease or ameliorate myocardial I/R injury, these include reperfusion controlling, cardioprotective events and management via various interventions.
Melatonin (N-acetyl 5-methoxy-tryptamine) is mainly secreted by the pineal gland to regulate sleep. Since 1993 when melatonin was first reported, a wide range of melatonin functions have been directly confirmed by multiple scientific studies . Melatonin and its metabolites protect against inflammation by regulating several inflammatory cytokines. Additionally, melatonin is a free radical scavenger and an antioxidant agent. Early studies have shown that melatonin exerts beneficial effects in the context of renal I/R, myocardial I/R, and hepatic I/R. The ability to protect against I/R injury may relate to the functions of melatonin as both an anti-inflammatory and an antioxidant agent .
Some authors show an anti-apoptotic action of melatonin in different organs of the body, such as thymus, kidney, brain and liver .
the current study is designed to investigate the protective effects of melatonin against myocardial I/R injury in patients undergoing coronary artery bypass grafting (CABG) surgery.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Bypass Grafting, Coronary Artery Disease
Keywords
CABG, melatonin, inflammation
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
22 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Melatonin group
Arm Type
Active Comparator
Arm Description
Melatonin Group (n=11) patients will receive 60 mg/day Melatonin capsule (M1) from the day five before surgery.
Arm Title
Control group
Arm Type
Placebo Comparator
Arm Description
Control group (n=11) patients will receive placebos with the same appearances and packaging at the same dose and time as those in the melatonin group.
Intervention Type
Dietary Supplement
Intervention Name(s)
Melatonin
Intervention Description
patients in the melatonin group will receive 60 mg/day Melatonin capsule (M1) from the day five before surgery.
Intervention Type
Other
Intervention Name(s)
placebo
Intervention Description
patients will receive capsules of the same size and color
Primary Outcome Measure Information:
Title
Nuclear factor-kB (NF-κB)
Description
Nuclear factor-kappa B (NF-κB) is a ubiquitous transcription factor that is involved in inflammatory and immune responses, as well as in regulation of expression of many other genes related to cell survival, proliferation, and differentiation
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
interleukin 6 il-6
Description
Interleukin-6 is a widely used cytokine that causes inflammation and oxidative stress, which would further result in cardiac and cerebral injury. The increased expression of interleukin-6 is closely related to atherosclerosis, myocardial infarction, heart failure and ischemic stroke. It is a key risk factor for these diseases by triggering inflammatory reaction and inducing other molecules release.
Time Frame
24 hours
Title
Tumor necrosis factor alpha TNF-α
Description
Tumor necrosis factor (TNF) is a multifunctional cytokine that plays important roles in diverse cellular events such as cell survival, proliferation, differentiation, and death. As a pro-inflammatory cytokine, TNF is secreted by inflammatory cells, which may be involved in inflammation-associated heart diseases.
Time Frame
24 hours
Title
cardiac troponins
Description
cardiac marker
Time Frame
24 hours
Other Pre-specified Outcome Measures:
Title
LVEF%
Description
left ventricular ejection fraction
Time Frame
24 hours
Title
Safety (Adverse effects from melatonin)
Description
Safety of melatonin
Time Frame
5 days
Title
hospital length of stay
Description
Duration of staying in hospital
Time Frame
5-7 days
Title
ICU length of stay
Description
Duration of staying in ICU
Time Frame
2-3 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients who will undergo elective CABG,
ready to participate in the study and
can be reached by phone
Exclusion Criteria:
• Patients who will require urgent surgery and won't have adequate time to take medications for 5 days,
Re-operative patients (CABG),
Off-pump CABG,
Patients who have concomitant renal failure,
Patients with severe respiratory problems.
Patients with previous stroke or significant cerebrovascular disease,
Patients with hepatitis b,c and HIV.
Inflammatory disease ex. Rheumatoid arthritis, psoriasis…,
Patients with ejection fraction (EF%) lower than 40%,
Patients undergo CABG surgery with simultaneous heart valve repair or replacement, resection of a ventricular aneurysm, or other operations.
Pregnancy and lactation.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
eman A. casper, masters
Phone
0201068731483
Email
drcasper912009@hotmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
sara M. Farid, PhD
Phone
01001232067
Email
sarah.farid@pharma.asu.edu.eg
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
eman A. casper, masters
Organizational Affiliation
Ain shams university , faculty of pharmacy
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Melatonin Impact on the Outcomes of Myocardial Ischemia/Reperfusion Injury During Coronary Artery Bypass Grafting Surgery
We'll reach out to this number within 24 hrs